Stocklytics Platform
Asset logo for symbol CRSP
CRISPR Therapeutics AG
CRSP60
$38.18arrow_drop_up0.96%$0.36
Asset logo for symbol CRSP
CRSP60

$38.18

arrow_drop_up0.96%
Key Stats
Open$37.79
Prev. Close$37.82
EPS-4.34
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range37.79
38.54
52 Week Range31.43
91.10
Ratios
EPS-4.34
Fundamentals
Payout Ratio-
Industry average yield2.87%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

CRSP-
US Healthcare Sector-
US Market-
check_circle

CRSP / Market

CRSP exceeded the US Market which returned 0.94% over the last twenty four hours.
warning

CRSP / Healthcare Sector

CRSP lose to the US Healthcare sector which returned 2.54% over the last twenty four hours.

CRISPR Therapeutics AG (CRSP) Statistics

CRISPR Therapeutics AG (CRSP) is a biotechnology company that focuses on gene-editing technology. The company's primary area of research is the development of CRISPR/Cas9 gene-editing tools, which have the potential to revolutionize the treatment of genetic diseases. CRISPR Therapeutics AG has a market capitalization of $7.5 billion and is headquartered in Switzerland. The company's stock, with the ticker symbol CRSP, is listed on the NASDAQ exchange. As of the latest valuation metrics, CRISPR Therapeutics AG has a price-to-earnings ratio of 57.13 and a price-to-sales ratio of 40.53.
From a fundamental perspective, CRISPR Therapeutics AG has shown strong growth in recent years. The company's revenue per share has been steadily increasing, indicating a growing top line. Additionally, CRISPR Therapeutics AG's enterprise to EBITDA ratio, which measures its profitability, stands at 27.85. This suggests that the company is generating healthy profits relative to its enterprise value. Furthermore, CRISPR Therapeutics AG has a profit margin of -80.69%, indicating that the company is currently operating at a loss.
add CRISPR Therapeutics AG to watchlist

Keep an eye on CRISPR Therapeutics AG

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has CRISPR Therapeutics AG (CRSP) stock's performance compared to its sector and the market over the past year?

Over the past year, CRISPR Therapeutics AG (CRSP) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 18.81%, CRISPR Therapeutics AG has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 34.40%, it has fallen short of the market average. This comparison highlights CRISPR Therapeutics AG's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of CRISPR Therapeutics AG (CRSP) stock?

The PE ratio for CRISPR Therapeutics AG (CRSP) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of CRISPR Therapeutics AG (CRSP) stock?

The Earnings Per Share (EPS) for CRISPR Therapeutics AG (CRSP), calculated on a diluted basis, is -$4.34. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of CRISPR Therapeutics AG (CRSP) stock?

The operating margin for CRISPR Therapeutics AG (CRSP) is -180.96%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of CRISPR Therapeutics AG (CRSP) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of CRISPR Therapeutics AG (CRSP) is -$447.31M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does CRISPR Therapeutics AG (CRSP) have?

CRISPR Therapeutics AG (CRSP) has a total debt of $223.69M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$74.56M.

Take Your Investments to a Whole New Level